Skip to main content
Numero verde Huntington
info@lirh.it
| Toll-free number
800 388 330
800 388 330
EN
Toggle Dropdown
EN
IT
Huntington's Disease
What is HD
Symptoms of Huntington’s Disease
How to treat the disease
Genetic testing
Huntington e genitorialità
Huntington’s Disease in children
History of Huntington’s Disease
HD Patient Journey
Italian White Paper on Huntington's Disease
Huntington's Disease management model
Who we are
LIRH Foundation
Our people
Our network
Our Team
What we do
Research
Care
Awareness
Annual Conference
Progetto S.M.A.R.T.
Get involved
Make a Donation
5xmille
Participate
Become a member
Solidary favors
Corporate donations
Clinical Trials
Why participate
Testimonies
News & media
Latest news
Events
Video
Webinar
Huntington Post
Media Kit
Documenti utili
Contacts
Where to find us
Questions and answers
Ask to expert
Get in touch
Careers
Menu
Home
Latest news
Preserving the Brain: LIRH Foundation joins Fondazione Prada's 'call to action'
EMA has agreed to evaluate the MAA for pridopidine for the treatment of Huntington's disease
Lega Italiana Ricerca Huntington continues to grow: LIRH Umbria is born!
Update from Skyhawk Therapeutics on the Phase 1 clinical trial with SKY-0515.
Today, on Women's Day, the LIRH Friuli Venezia Giulia Association is officially born.
Pridopidine for Huntington's disease now available through an expanded access/compassionate use program
Predicting the Severity of Imminent Huntington Disease
Breakthrough in the study of Huntington's disease: an alteration in the pediatric HD is not present in the adult HD
The phase 2A Pivot-HD clinical study for Huntington disease starts today in Italy
The results of the PROOF-HD study in Huntington's disease are not as expected
Rare Disease Day 2023. Doing well is possible. The example of Huntington's disease.
Clinical trials on Huntington Disease. LIRH Annuale Conference: Rome, December 3, 2022
Huntington's disease trials: update on Vibrant-HD (Novartis) and AMT-130 (uniQure).
LIRH Foundation sheds a light on Florence for Huntington's disease
LIRH Sardegna and LIRH Foundation meet the HD families to talk about research and care
Huntington patients at the forefront of the right to care: the LIRH Sardinia Association was born
Rare Disease Day 2022: The colors of Huntington Disease
First Patients dosing in European Open-Label AMT-130 Gene Therapy trial for Huntington's
Oral drugs, the new frontier in fighting the cause of Huntington's disease
Huntington's signs in the first months of life described in a recent study
Roche announced a phase II study with tominersen. Do we know enough?
Hobbies help get better, according to a study conducted on people with Huntington's disease.
Clinical Update on First Patients in Phase I/II Clinical Trial Gene Therapy for the Treatment of Huntington’s Disease
Pagination
Current page
1
Page
2
Page
3
Page
4
Next page
››
Last page
Last »
Everything is possible, if we are many!
DONATE
GET INVOLVED
5x1000
1
1
Huntington's Disease
What is HD
Symptoms of Huntington’s Disease
How to treat the disease
Genetic testing
Huntington e genitorialità
Huntington’s Disease in children
History of Huntington’s Disease
HD Patient Journey
Italian White Paper on Huntington's Disease
Huntington's Disease management model
Who we are
LIRH Foundation
Our people
Our network
Our Team
What we do
Research
Care
Awareness
Annual Conference
Progetto S.M.A.R.T.
Get involved
Make a Donation
5xmille
Participate
Become a member
Solidary favors
Corporate donations
Clinical Trials
Why participate
Testimonies
News & media
Latest news
Events
Video
Webinar
Huntington Post
Media Kit
Documenti utili
Contacts
Where to find us
Questions and answers
Ask to expert
Get in touch
Careers